Stenocare

1.25 DKK

-7.41 %

Less than 1K followers

STENO

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-7.41 %

-11.35 %

-15.54 %

-26.47 %

-1.19 %

+188.02 %

-73.92 %

-86.84 %

-90.84 %

Stenocare is a Danish supplier of medical cannabis. Stenocare is the first player to have started sale of medical cannabis-based oils in Denmark. The company is now looking towards further European markets for its products. Stenocare is based in Randers, Denmark.

Market cap

54.25M DKK

Turnover

402.07K DKK

Revenue

7.02M

EBIT %

-25.26 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

All

Press releases

3rd party

ShowingAll content types

Regulatory press release2/26/2026, 7:00 AM

STENOCARE: Interim report fourth quarter and Financial Statement Release 2025

Press release2/11/2026, 7:00 AM

STENOCARE A/S positions for First-Mover Advantage in France With Strategic Partnership, Product Filing, and National Distribution Partnership

Press release1/27/2026, 3:27 PM

STENOCARE: Stenocare Kicks Off Strategic Partnership with WEECO to Launch New Astrum Oil Product in Germany

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/30/2025, 10:19 AM

Trading in STENOCARE shares by closely related party to board member

Press release11/21/2025, 5:41 AM

BioStock: Stenocare acquires Canngros

Press release11/19/2025, 6:56 PM

STENOCARE share analyst's comments on the CannGros acquisition

Regulatory press release11/18/2025, 8:59 AM

STENOCARE: Correction of total shares issued and total nominal share capital:

Regulatory press release11/17/2025, 4:56 PM

STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026 break even goal

Regulatory press release11/17/2025, 4:01 PM

STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026 break even goal

Regulatory press release10/22/2025, 6:00 AM

STENOCARE: Interim report third quarter 2025

Regulatory press release8/27/2025, 7:30 PM

Trading in STENOCARE shares by closely related party to board member

Regulatory press release8/21/2025, 6:00 AM

STENOCARE: Interim report second quarter 2025

Third party research5/19/2025, 8:05 AM

STENOCARE: Time to Capitalize on STENOCARE 3.0 - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has recently launched a premium product, Astrum oil, which Analyst Group sees as an important...

Regulatory press release5/15/2025, 9:36 AM

Communiqué from the Annual General Meeting of STENOCARE

Third party research5/9/2025, 5:25 AM

Analyst Group Comment on STENOCARE's Q1-report

STENOCARE A/S (STENOCARE or the “Company”) published on May 8th the Company’s Q1-report for 2025.

Regulatory press release5/8/2025, 6:00 AM

STENOCARE: Interim report first quarter 2025

Press release5/2/2025, 12:35 PM

Medical Cannabis Made Permanent in Denmark: Major Milestone for Patients and STENOCARE

Regulatory press release4/22/2025, 1:01 PM

Notice to Annual General Meeting in STENOCARE A/S

Third party research4/4/2025, 7:20 AM

Analyst Group Comment on STENOCARE ASTRUM 10-10 Oil Being Approved for Reimbursement in Germany

On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for reimbursement in Germany through major health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible ...

Press release4/3/2025, 6:00 AM

STENOCARE ASTRUM 10-10 Oil Product Approved for Reimbursement in Germany

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.